CRL · Earnings call · 2026Q2T · Full report
AI Research Partnerships
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 6 · Surprise 42 · In source text
Charles River collaborated with Eli Lilly’s TuneLab drug discovery platform to provide nonclinical wet-lab testing expertise for Lilly’s AI and machine-learning drug discovery model. Management emphasized that AI-enabled molecule design and target identification will still require traditional in vivo and in vitro validation and regulated safety assessment. The company is also deploying an enhanced AI-enabled digital pathology workflow intended to reduce standard pathology timelines by at least one week and improve pathologist efficiency. Through its PathoQuest acquisition, Charles River added an in vitro next-generation sequencing solution and is using it in a collaboration with Arovella Therapeutics for cell and gene therapy testing.
Key facts
- In June, Charles River announced a collaboration with Eli Lilly's TuneLab drug discovery platform to provide nonclinical or wet lab testing expertise to help build and optimize Lilly's AI and machine learning drug discovery model.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. established a NAMs Scientific Advisory Board last year and hired a leader from the industry to be Chief Scientific Officer to focus on NAMs development.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | In June, Charles River announced a collaboration with Eli Lilly's TuneLab drug discovery platform to provide nonclinical or wet lab… |